Ameriprise’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Ameriprise’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,253	Closed	-$28K	–	3818
2018 Q4	$28K	Buy	1,253 +28	+2%	+$1.09K	﹤0.01%	3587
2018 Q3	$68K	Buy	1,225 +50	+4%	+$3.19K	﹤0.01%	3646
2018 Q2	$84K	Buy	1,175 +50	+4%	+$3.53K	﹤0.01%	3579
2018 Q1	$69K	Hold	1,125	–	–	﹤0.01%	3578
2017 Q4	$142K	Hold	1,125	–	–	﹤0.01%	3530
2017 Q3	$154K	Sell	1,125 -15	-1%	-$2.01K	﹤0.01%	3561
2017 Q2	$162K	Buy	+1,140	New	+$176K	﹤0.01%	3605
2015 Q3	–	Sell	-2,798	Closed	-$2.66M	–	4010
2015 Q2	$2.66M	Buy	2,798 +1,216	+77%	+$994K	﹤0.01%	2572
2015 Q1	$1.16M	Sell	1,582 -1,333	-46%	-$1M	﹤0.01%	2861
2014 Q4	$2.31M	Sell	2,915 -566	-16%	-$305K	﹤0.01%	2500
2014 Q3	$1.39M	Buy	3,481 +3,479	+173,950%	+$932K	﹤0.01%	2651
2014 Q2	$0	Buy	+2	New	+$429	﹤0.01%	5698
2013 Q4	–	Sell	-36	Closed	-$8K	–	5519
2013 Q3	$8K	Hold	36	–	–	﹤0.01%	5047
2013 Q2	$5K	Buy	+36	New	+$5.7K	﹤0.01%	5154

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise's TTPH Position: Q1 2019 in Review

Ameriprise sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2019, closing a stake of 1,253 shares — an estimated $28K sold.

Ameriprise first reported a position in TTPH in Q2 2013 and held it in 14 quarters. The position peaked at $2.66M in Q2 2015. 78 funds tracked by Wall St. Rank hold TTPH as of Q1 2019.

Ameriprise reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Ameriprise sold 1,253 Tetraphase Pharmaceuticals, Inc. shares in Q1 2019, an estimated $28K.
Ameriprise first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2013 and held it in 14 quarters.
Ameriprise's Tetraphase Pharmaceuticals, Inc. position peaked at $2.66M in Q2 2015.
78 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2019.

Based on Ameriprise's 13F filing for Q1 2019, filed 15 May 2019.